Digestive Diseases
| Crohn's Disease
Digestive Diseases
Crohn's Disease
Risankizumab versus ustekinumab for patients with moderate to severe Crohn’s disease: results from the Phase 3b SEQUENCE study
book_2
Source:
UEG Week 2023 - Oral session
calendar_today
Published on Medfyle:
November 2023
import_contacts
7
min
headphones
4
min
In this medfyle
Eagerly awaited results from the SEQUENCE study, which directly compares the efficacy and safety of IL-23 inhibition with IL12/23 inhibition using risankizumab and ustekinumab both of which are approved for the treatment of Crohn’s disease. These data help clinicians differentiate between the treatment options for the management of Crohn's disease that can best help patients reach treatment goals.
Expert commentary
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the UEG Week 2023.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content.
©2023 Infomedica-Medfyle. All rights reserved.
